Sentry stands with Ryan White Clinics as study highlights importance of funding and 340B program in managing HIV/AIDS epidemic
DEERFIELD BEACH, Fla., Oct. 26, 2020
DEERFIELD BEACH, Fla., Oct. 26, 2020 /PRNewswire/ — Sentry Data Systems, Inc., the nation’s leader in pharmacy procurement, compliance and utilization management, announced today a new analysis from Ryan White Clinics for 340B Access, a nonprofit organization of HIV/AIDS medical providers of which Sentry is a benefactor. The study highlights the importance of Ryan White Clinics in effectively treating the conditions, and it suggests that any reductions in federal funding or to the 340B drug benefits the clinics depend on would have a devastating effect on efforts to manage the public health crisis.
“Ryan White Clinics are an indispensable part of our nation’s healthcare safety net and play an effective role in treating an especially vulnerable group of Americans,” said Travis Leonardi, founder and CEO of Sentry Data Systems. “Sentry is proud to support Ryan White Clinics for 340B Access and its members through advocacy, technology and the expertise they need to maximize their 340B benefits and continue providing high-quality care to their patients.”
Ryan White Clinics for 340B Access (RWC-340B) is a national organization of health care clinics and service providers that receive support under the federal Ryan White CARE Act, which provides funds for services used primarily by indigent and uninsured people with HIV/AIDS. Ryan White providers are also eligible for the federal 340B Drug Discount Program and use it to expand affordable access to expensive and life-saving HIV/AIDS medications. Sentry is a Platinum Level Benefactor of RWC-340B and has made a significant donation to the nonprofit in 2020 to help share important 340B-related information with its members.
The new data-driven white paper comes as the 340B program is under assault from drug manufacturers and as the federal government is pushing Medicare Part B rate cuts for 340B drugs. It states that any reduction in resources, including 340B Drug Pricing Program savings, could have long-term consequences for patients served through Ryan White HIV/AIDS Program-funded clinics, including disruptions in care and treatment, adverse health outcomes, or increased healthcare expenses.
On Oct. 9, RWC-340B filed a federal lawsuit against the U.S. Department of Health and Human Services and its Health Resources and Services Administration. It seeks action against four drug manufacturers that have refused to sell 340B-discounted drugs to covered entities when ordered through a contract pharmacy.
“Given the sustained and serious threats to the 340B program, this white paper and analysis reveals important facts about the critical role Ryan White clinics play in the safety net,” said Mark Malahosky, RPh BPharm, Vice President, Pharmacy Services, Trillium Health and Treasurer of Ryan White Clinics for 340B Access. “This report proves what we’ve known all along: harm to the 340B program means dangerous consequences for public health and
A Russian woman applies moxibustion to a boy to prevent virus. Photo: Courtesy of Huang Guorong
The Traditional Chinese Medicine (TCM) has a history of more than 20 years spreading in Russia, especially among governmental officials and businessmen. With the development of COVID-19 epidemic in Russia, TCM has been gaining recognition in preventing virus and strengthening treatment.
The Global Times has learned that the wide use of TCM, such as Lianhua Qingwen Capsule, a Chinese herbal product, to treat COVID-19 has also helped TCM gain more attention in Russia.
As early as in April, Lianhua Qingwen capsule has been approved for use in COVID-19 treatments in China. Beijing TCM authorities said the capsule can alleviate COVID-19 symptoms such as fever, cough and fatigue.
Zhang Boli, an academician with the Chinese Academy of Engineering, told the media in April that Russia is considering approving the capsule as a medicine.
A Global Times reporter in Moscow noticed that a few Russian medicine websites translated the specification of the capsule in detail and the medicine can be purchased online.
Huang Guorong, a Moscow-based Chinese doctor who graduated from the Beijing University of Chinese Medicine, said that more Russians have been trying TCM to prevent COVID-19 since the epidemic developed in the country.
“Compared with the Western medicine using antibiotic, the TCM focuses on the mediation of the whole body, which defends the body through strengthening your immunity,” he told the Global Times.
Even though there have been introductions on TCM on Russia’s TV or newspapers from time to time, and most people in the country have heard about it, only a small number have tried it.
“In Russia, TCM is not cheap,” he said. “And some kinds of herbs have not been approved by the medicine authority in Russia yet.”
But it is understood that “the rich and powerful people would recommend their friends to try TCM once they found it useful,” Huang said.
Li Yunhai, another prestigious Chinese doctor in Moscow, said some Russian officials visited TCM doctors during the epidemic for prevention and treatment.
Li has received a Russian official who suffered from high blood pressure, weakness and asthma after recovering from COVID-19. Li gave him skin scraping, acupuncture and herbs, and after one course of treatment, the official recovered.
Huang would not disclose how many clients from the high-level government officials he has received, but said they include Moscow’s district officials and members of the State Duma.
Though he has not heard if President Putin has accepted TCM treatment, he does know a Russian friend who wrote to the president’s office to advocate the use of TCM in COVID-19 prevention and treatment across the country. “But we haven’t received a reply yet,” Huang said.
Former Russian president Boris Yeltsin had a TCM therapist, Huang said, adding that the 1990s was the time when the TCM was introduced to Russia and became popular among the officials and business people, he said.
Moreover, Tibetan medicine, similar in some ways to
The reproduction rate of coronavirus in the UK is 1.3 to 1.5, meaning there is still “widespread growth” across the country.
Last week the figure was given as 1.2 to 1.5.
Experts on the government’s Scientific Advisory Group for Emergencies (SAGE) published the latest figures on Friday.
A statement from SAGE said: “It is SAGE’s expert view… that this week’s estimates are reliable, and that there is still widespread growth of the epidemic across the country.
“SAGE is confident that the transmission is not slowing. There is no clear evidence that the epidemic’s trajectory has changed in the past month.
“While the R value remains above 1.0, infections will continue to grow at an exponential rate. This is currently the case for every region of England and all have positive growth rates, reflecting increases in the number of new infections across the country.”
Watch: Coronavirus: what is the R0 reproduction rate?
The growth rate is between +4% and +7% meaning the number of new infections is growing by 4% to 7% every day, a slight decrease from 4% to 9% last week.
The data comes after a new three-tier system was introduced in England to classify areas according to COVID-19 infection risk.
The Liverpool City region became the first to enter the ‘very high’ Tier 3 band on Wednesday, with local leaders in Manchester becoming embroiled in a bitter battle with government to resist the city and surrounding areas also being upgraded from Tier 2 to Tier 3.
In these areas the R rate has remained at a similar level to the previous week, but the figures for the south west of England are now the highest in the country, with an R rate of 1.3 to 1.6 and a growth rate of 6% to 10%.
Boris Johnson has said his “whack-a-mole” strategy of localised lockdowns could help prevent another nationwide lockdown, but scientific advisors to the government have questioned whether the localised tier-system could have come too late.
Scientific advisor Graham Medley, from the London School of Hygiene and Tropical Medicine, said of the likelihood of success of local lockdown measures: “I really hope that they are [successful] but the general feeling is that they might not be, that we might have to have much more of an approach and that this three week delay between the impact of interventions and it affecting hospitalisations means we are already going to be close to where we were in April in two or three weeks time.”
Medley was speaking to BBC Radio 4’s Today programme ahead of an interview with Dominic